166. Pseudoxanthoma elasticum Clinical trials / Disease details
Clinical trials : 15 / Drugs : 27 - (DrugBank : 5) / Drug target genes : 5 - Drug target pathways : 28
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04441671 (ClinicalTrials.gov) | December 8, 2020 | 20/1/2020 | Oral Pyrophosphate Absorption in PXE Disease | Oral Disodiumpyrophosphate (Na2H2PPi) Absorption in Pseudoxanthoma Elasticum (PXE) | Pseudoxanthoma Elasticum | Drug: Disodium Pyrophosphate | Tampere University Hospital | UMC Utrecht;Hungarian Academy of Sciences | Withdrawn | 18 Years | 80 Years | All | 0 | Phase 2 | NULL |
| 2 | EUCTR2019-002109-24-FI (EUCTR) | 01/08/2019 | 01/07/2019 | Oral Pyrophosphate Absorption in PXE Disease | Oral Disodiumpyrophosphate (Na2H2PPi) Absorption in Pseudoxanthoma Elasticum - Oral Pyrophosphate Absorption in PXE | Pseudoxanthoma elasticum;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: Disodiumpyrophosphate | Tampere University Hospital | NULL | Not Recruiting | Female: yes Male: yes | 10 | Phase 2 | Finland |